{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mihalik NE"],"funding":["NIBIB NIH HHS","NCI NIH HHS","NIGMS NIH HHS","NIH HHS"],"pagination":["191"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8361900"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(5)"],"pubmed_abstract":["Granulocyte-macrophage colony-stimulating factor (GM-CSF) has demonstrated notable clinical activity in cancer immunotherapy, but it is limited by systemic toxicities, poor bioavailability, rapid clearance, and instability in vivo. Nanoparticles (NPs) may overcome these limitations and provide a mechanism for passive targeting of tumors. This study aimed to develop GM-CSF-loaded PLGA/PLGA-PEG NPs and evaluate them in vitro as a potential candidate for in vivo administration. NPs were created by a phase-separation technique that did not require toxic/protein-denaturing solvents or harsh agitation techniques and encapsulated GM-CSF in a more stable precipitated form. NP sizes were within 200 nm for enhanced permeability and retention (EPR) effect with negative zeta potentials, spherical morp"],"journal":["AAPS PharmSciTech"],"pubmed_title":["Formulation and In Vitro Characterization of PLGA/PLGA-PEG Nanoparticles Loaded with Murine Granulocyte-Macrophage Colony-Stimulating Factor."],"pmcid":["PMC8361900"],"funding_grant_id":["R01 CA194013","P20 GM121322","R00 EB023990","S10 OD016165","R21 EB028553","P20 GM103434","P20 GM109098","U54 GM104942","R01 CA192064","T32 GM133369"],"pubmed_authors":["Eubank TD","Wen S","Driesschaert B","Mihalik NE"],"additional_accession":[]},"is_claimable":false,"name":"Formulation and In Vitro Characterization of PLGA/PLGA-PEG Nanoparticles Loaded with Murine Granulocyte-Macrophage Colony-Stimulating Factor.","description":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) has demonstrated notable clinical activity in cancer immunotherapy, but it is limited by systemic toxicities, poor bioavailability, rapid clearance, and instability in vivo. Nanoparticles (NPs) may overcome these limitations and provide a mechanism for passive targeting of tumors. This study aimed to develop GM-CSF-loaded PLGA/PLGA-PEG NPs and evaluate them in vitro as a potential candidate for in vivo administration. NPs were created by a phase-separation technique that did not require toxic/protein-denaturing solvents or harsh agitation techniques and encapsulated GM-CSF in a more stable precipitated form. NP sizes were within 200 nm for enhanced permeability and retention (EPR) effect with negative zeta potentials, spherical morp","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-04-22T21:53:48.143Z","creation":"2025-04-06T03:52:32.076Z"},"accession":"S-EPMC8361900","cross_references":{"pubmed":["34169366"],"doi":["10.1208/s12249-021-02049-z"]}}